Cochrane · systematic review · CD004773
Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people
Awotiwon, AA, Johnson, S, Rutherford, GW, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 62.5%Moderate 3 · 37.5%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antifungal prophylaxis versus no antifungal prophylaxis for preventing cryptococcal disease in HIV‐positive people
Population: people who are HIV‐positive
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Antifungal prophylaxis vs no antifungal prophylaxis | RR 1.07 [0.8, 1.43] | 6 studies · 3220 participants | Low Downgraded: imprecision, inconsistency, indirectness |
Cryptococcal disease occurrence Antifungal prophylaxis vs no antifungal prophylaxis | RR 0.29 [0.17, 0.49] | 7 studies · 5000 participants | Moderate Downgraded: imprecision, indirectness |
Mortality due to cryptococcal disease Antifungal prophylaxis vs no antifungal prophylaxis | RR 0.29 [0.11, 0.72] | 5 studies · 3813 participants | Moderate Downgraded: imprecision, indirectness |
Clinical resistance of Candida species to fluconazole Antifungal prophylaxis vs no antifungal prophylaxis | RR 0.93 [0.56, 1.56] | 3 studies · 1198 participants | Low Downgraded: imprecision, inconsistency |
Microbiological resistance of Candida to fluconazole: surveillance sampling Antifungal prophylaxis vs no antifungal prophylaxis | RR 1.25 [1, 1.55] | 3 studies · 539 participants | Low Downgraded: imprecision, indirectness |
Treatment discontinuation Antifungal prophylaxis vs no antifungal prophylaxis | RR 1.01 [0.91, 1.13] | 4 studies · 2317 participants | Moderate Downgraded: indirectness |
Any serious adverse event Antifungal prophylaxis vs no antifungal prophylaxis | RR 1.08 [0.83, 1.41] | 4 studies · 888 participants | Low Downgraded: imprecision, indirectness |
Any adverse events Antifungal prophylaxis vs no antifungal prophylaxis | RR 1.07 [0.88, 1.3] | 4 studies · 2317 participants | Low Downgraded: inconsistency, indirectness |